Company news

Remegen Co. Ltd. Class A (SSE:688331) news

Remegen Co. Ltd. Class A news releases on 6ix. Latest, Sep 8, 2026: "REMEGEN CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective…

Remegen Co. Ltd. Class A (SSE:688331) news

Press releases & updates

"REMEGEN CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

"REMEGEN CO., LTD."Announcement on Adjustment of Members of Special Committees of the Board of Directors

"REMEGEN CO., LTD."Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026

"REMEGEN CO., LTD."Announcement on Progress of the First Repurchase of Company Shares in 2026 through Call Auction

"REMEGEN CO., LTD."Announcement on the First Share Repurchase through Call Auction in 2026

"REMEGEN CO., LTD."Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning First Share Repurchase in 2026

"REMEGEN CO., LTD."Announcement on Resolutions of the 2nd Meeting of the 3rd Board of Directors

Announcement on Circulation of Restricted Shares in Initial Public Offering

Announcement on Election of Employee Representative Directors for the 3rd Board of Directors

Announcement on Voluntary Disclosure of the Conditional Marketing Application for Telitacicept for the Treatment of IgA Nephropathy

Notice on Convening the 2025 Annual General Meeting

Announcement on Resolutions of the 38th Meeting of the 2nd Board of Directors

Announcement on Participation in the "Dialogue on Growth" 2025 and Q1 2026 Collective Performance Briefing

Report for Q1 2026

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference

Announcement on Voluntary Disclosure of Approval of Marketing Application for Vedicizumab as the First-line Treatment for HER2-Low Expressing Urothelial Carcinoma

Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by Dual-antibody ADC Drug RC288 for Injection

2025 Annual Report

Announcement on Voluntary Disclosure of Approval of Marketing Application for Vedicizumab the Treatment of HER2-Low Expressing Breast Cancer with Liver Metastasis

Announcement on Changing Signatory Certified Public Accountant

Earnings Preannouncement for 2025

Announcement on Vesting Results of Relevant Rights in the Related Vesting Period of the 2022 and 2023 A-share Restricted Stock Incentive Plans and Shares Listing

Announcement on Completion of Initial Share Repurchase and Implementation of Share Repurchase Plan

Announcement on Adjusting Upper Limit of Shares Repurchase Price

Announcement on Signing a Licensing Agreement with AbbVie

Announcement on Progress in Repurchasing Shares through Call Auction

Announcement on Canceling Some Restricted Stock Granted but Not Yet Vested in 2022 A-share Restricted Stock Incentive Plan

Announcement on Obtaining Letter of Commitment for Special Loans for Stock Repurchase from Financial Institution

Announcement on Resolutions of the 32nd Meeting of the 2nd Board of Directors

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Amending Some Governance Systems of the Company

Announcement on 1st Vesting Result of the 1st Vesting Period for the Reserved Grant of Type B Interests under the 2022 A-share Restricted Stock Incentive Plan and Lifting of Trading Restrictions

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Announcement on Resolutions of the 30th Meeting of the 2nd Board of Directors

Announcement on Estimated Daily Related Party Transactions in 2026-2028

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025

2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

2025 Semi-annual Report

RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China

RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Announcement on Resolutions of the 2024 Annual General Meeting, the 1st A-Share Shareholders' Meeting and the 1st H-Share Shareholders' Meeting in 2025